Growth Potential Perthera demonstrates a scalable AI-driven precision oncology platform with broad adoption among oncologists (1,500+) across 600+ cancer centers, indicating a sizable target base for upsell of Perthera Report Pancreatic and related modules.

Executive appointees Recent leadership appointments including a new CEO, CMO, and CMO indicate a strategic pivot and investment in market expansion, providing opening for partner-focused initiatives, co-marketing, and enterprise sales conversations.

Clinical validation Clinical backing showing improved survival and real-world outcomes supports value-based selling and payer conversations, enabling pilots or expanded contracts with hospital systems seeking proven AI oncology decision support.

Pancreatic focus Introduction of Perthera Report Pancreatic positions the company in a high-need specialty segment, offering opportunities to partner with GI and pancreatic cancer programs, and to bundle with existing GI or chemotherapy pathways.

Partnership momentum Active collaborations and joint studies with Jefferson and ongoing GI precision oncology initiatives create collaboration-backed entry points for enterprise deals, data partnerships, and expanded RWE-enabled offerings.